CONTACT: JENNIFER CRONIN
2130 Medical Laboratories
Iowa City IA 52242
(319) 335-6660; fax (319) 335-9917
UI developing gene therapy to help reduce problems with organ transplants
IOWA CITY, Iowa -- Someday doctors may be able to reduce the risk of
organ rejection in transplant patients, thanks to a gene therapy that University
of Iowa researchers are designing.
While the UI research has focused on liver transplantation, the new
therapy also could help to decrease the damage that heart attacks cause
and may even be useful for preventing problems before they occur.
"This type of gene therapy for acquired disease is part of an emerging
field of therapeutics," said John F. Engelhardt, Ph.D., UI associate
professor of anatomy and cell biology, and the project's principal investigator.
"Its application is not limited to the liver."
A team of UI investigators currently is using models to test the gene
therapy as the group moves towards the therapy's clinical application for
liver transplantation. Different elements of the UI research appeared in
the June issue of Nature Medicine and more recently in the October issue
The UI-designed gene therapy would target ischemia-reperfusion injuries.
When organs in the body have reduced blood flow such as during transplants
and heart attacks, they lack adequate oxygen to support life. While this
aspect, called ischemia, is not itself significantly damaging to cells,
when blood flow is re-established (called reperfusion), the high levels
of oxygen create damaging compounds.
"These compounds can signal cells to commit suicide," Engelhardt
said. "We have designed a gene therapy that creates a garbage disposal
of sorts for clearing these damaging compounds from the body before cell
death can occur."
Using an engineered defective common cold virus, the researchers transfer
a therapeutic gene, called mitochondrial superoxide dismutase (MnSOD),
to all liver cells in order to reduce ischemia-reperfusion induced damage.
"The application of this work will hopefully lead to treatments
that can increase the success of organ transplantation," Engelhardt
said. "The investigators are using similar approaches to reduce the
damage caused by heart attacks as well."
By using the gene therapy as soon as possible after the heart attack
occurs, physicians can hopefully help the damaged cells to repair themselves,
Engelhardt said. This therapy also could help those at high risk of heart
attacks by reducing damage from ischemic heart disease.
This type of gene therapy research is part of the UI's newly funded
Gene Therapy Core Center, which Engelhardt will direct. The National Institutes
of Health and the Cystic Fibrosis Foundation recently awarded the UI an
$8 million, five-year grant to develop the center, which is expected to
be operational by November. The UI is one of two institutions nationwide
that received funding this fiscal year to establish such a center.